Compare RNA & TNET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNA | TNET |
|---|---|---|
| Founded | 2012 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 2.6B |
| IPO Year | 2020 | 2014 |
| Metric | RNA | TNET |
|---|---|---|
| Price | $71.76 | $57.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 4 |
| Target Price | ★ $69.26 | $63.33 |
| AVG Volume (30 Days) | ★ 2.9M | 337.7K |
| Earning Date | 11-10-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 1.93% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.65 |
| Revenue | $20,868,000.00 | ★ $4,971,000,000.00 |
| Revenue This Year | $64.11 | $2.83 |
| Revenue Next Year | $37.25 | $2.67 |
| P/E Ratio | ★ N/A | $21.52 |
| Revenue Growth | ★ 106.27 | N/A |
| 52 Week Low | $21.51 | $54.22 |
| 52 Week High | $71.79 | $97.02 |
| Indicator | RNA | TNET |
|---|---|---|
| Relative Strength Index (RSI) | 77.56 | 45.54 |
| Support Level | $71.42 | $57.11 |
| Resistance Level | $71.76 | $59.13 |
| Average True Range (ATR) | 0.41 | 1.46 |
| MACD | -0.73 | 0.39 |
| Stochastic Oscillator | 88.32 | 57.86 |
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
Trinet Group Inc outsourced payroll and human capital management solutions for small and midsize businesses via a professional employer organization model. Under the PEO model, TriNet enters a co-employment arrangement and acts as the employer of record for administrative and regulatory purposes for clients' employees, known as worksite employees. Clients leverage the scale and expertise of TriNet to access competitive employee benefits, share employment risk liability, access compliance support, and outsource mission-critical day-to-day HR functions such as payroll and tax administration. Following the acquisition of Zenefits and Clarus R+D in 2022, TriNet derives the minority of its revenue from self-service HCM software and R&D tax credit services.